skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical approach in treatment of resistant hypertension

Review

(3865) Views  (1324) Full article downloads

Authors: Jennifer Frank, David Sommerfeld

Published Date July 2009 Volume 2009:2 Pages 9 - 23
DOI: http://dx.doi.org/10.2147/IBPC.S4315

Jennifer Frank, David Sommerfeld

University of Wisconsin School of Medicine and Public Health, Department of Family Medicine, Appleton, WI, USA

Abstract: Resistant hypertension, defined as failure to achieve target blood pressure despite the use of optimal or maximum doses of at least 3 agents, one of which is a diuretic, or requiring 4 or more medications to achieve blood pressure goal, is likely to affect up to 20% of all patients with hypertension. Apparent resistant hypertension may be caused by medication nonadherence, substances that either interfere with antihypertensive mediations or cause blood pressure elevation, and under- or inappropriate medication treatment. Certain patient characteristics are associated with the presence of resistant hypertension and include chronic kidney disease, diabetes, obesity, and presence of end-organ damage (microalbuminuria, retinopathy, left-ventricular hypertrophy). Secondary causes of resistant hypertension are not uncommon and include obstructive sleep apnea, chronic kidney disease, primary aldosteronism, renal artery stenosis, pheochromocytoma, and Cushing’s disease. Initial medication management usually includes adding or increasing the dose of a diuretic, which is effective in lowering the blood pressure of a large number of patients with resistant hypertension. Additional management options include maximizing lifestyle modification, combination therapy of antihypertensive agents depending on individual patient characteristics, adding less-commonly used fourth- or fifth-line antihypertensive agents, and referral to a hypertension specialist.

Keywords: resistant hypertension, blood pressure, diuretic








Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Cardiovascular disease in patients with chronic kidney disease
Can nocturnal hypertension predict cardiovascular risk?
Evidence-based approach for managing hypertension in type 2 diabetes
Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill
Role of aliskiren in blood pressure control and renoprotection
Treatment of anemia in chronic kidney disease: known, unknown, and both
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University